Cancer News

FDA Grants Accelerated Approval to Brukinsa for Mantle Cell Lymphoma (12/05/2019)

Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial The Food and Drug Administration (FDA) has granted accelerated approval to Brukinsa (zanubrutinib; BeiGene USA) for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy. Zanubrutinib is a small molecule inhibitor of Bruton tyrosine... Continue Reading

FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma (11/06/2017)

The U.S. Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.  Mantle cell lymphoma is a particularly aggressive cancer and new treatments are needed for patients who have not responded to treatment or have relapsed, Mantle …

Continue reading "FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma"